Cas:157069-48-2 4-(4H-1,2,4-triazol-4-yl)benzoic acid manufacturer & supplier

Chemical Name:4-(4H-1,2,4-triazol-4-yl)benzoic acid

CAS.NO:157069-48-2

Synonyms:f2167-0140;4-(4H-1,2,4-triazol-4-yl)benzoic acid

Molecular Formula:C₉H₇N₃O₂

Molecular Weight:189.17100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:424.1ºC at 760 mmHg

Density:1.39g/cm3

Index of Refraction:1.673

PSA:68.01000

Exact Mass:189.05400

LogP:0.96550

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like f2167-0140 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(4H-1,2,4-triazol-4-yl)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,f2167-0140 Use and application,f2167-0140 technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. 4-(4H-1,2,4-triazol-4-yl)benzoic acid manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance. 4-(4H-1,2,4-triazol-4-yl)benzoic acid supplier There are more than 4,700 different PFAS chemical compounds, researchers said. Since the 1950s, they have been widely used in a number of consumer products, including stain-repellent fabrics, nonstick cookware, polishes, waxes, paints and cleaning products, according to the U.S. Environmental Protection Agency. 4-(4H-1,2,4-triazol-4-yl)benzoic acid vendor In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. 4-(4H-1,2,4-triazol-4-yl)benzoic acid factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.